ArticleEcancermedicalscience2025
Neoadjuvant lenvatinib in a patient with invasive poorly differentiated thyroid cancer.
Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neoadjuvant Therapies for Thyroid Cancer: A Scoping Review.The Laryngoscope · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A limited number of case reports have investigated the role of tyrosine kinase inhibitors as neoadjuvant therapy in locally invasive poorly differentiated thyroid cancer (PDTC). Case report: A 69-year-old female patient presented with a large mass in the right thyroid lobe measuring 10 × 8 cm. A computed tomography scan showed a mass with no cleavage plane between the tumour and both the laryngotracheal and esophageal right lateral wall. A core needle biopsy was performed and confirmed PDTC. The case was considered unresectable. After a trial of neoadjuvant lenvatinib was administered, a partial response of 50% was achieved and surgery could be performed with favourable surgical outcomes. The patient did not resume lenvatinib after surgery, as no evidence of structural disease was found. At publication, she remains free of structural disease with an incomplete biochemical response. Conclusion: Neadjuvant lenvatinib can be a therapeutic option to reduce primary tumour extent, in order to perform surgery and achieve better outcomes. However, this requires a highly selected patient group. Neoadjuvant-targeted therapy holds significant promise and warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.